AXCELIS TECHNOLOGIES INC (ACLS): what the price assumes

In the published model solve dated 2026-Q2, anchored at $115.08, AXCELIS TECHNOLOGIES INC (ACLS) is priced for today's economics sustained for ~18.3 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-09-07 · Exported: 2026-09-09 · Source: https://boothcheck.com/report/ACLS

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 13.9% cost of capital; growth searched up to the 25% self-funding ceiling.

How unusual the bet is: n/a

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.9%); the inversion above states its own rate.

Per-Model Detail (n=15)

Solvency

Bullet Takeaways

• Revenue went backwards last year and the gross margin did not, which is the single most useful fact about this company: the 10-K reports "Revenue for 2025 was $839.0 million, compared to $1,017.9 million in 2024" while gross margin held at 44.9%.
• Systems backlog is the leading indicator and it has thinned, falling to $457.0 million at the end of 2025 from $645.8 million a year earlier, so the recovery has to show up in orders before it shows up anywhere else.
• Roughly a third of revenue now comes from servicing an installed base of about 3,400 tools in 27 countries, which is the part of the business that does not stop when customers stop buying machines.

Bull Case

Semiconductor equipment makers are among the hardest companies in the market to value, for a reason the filing itself states better than most sell-side notes: the industry "requires ongoing investments in operations and research and development that are not easily adjusted to reflect changes in revenue. As a result, profitability and cash flows can fluctuate more widely than revenue." Translated, that means the earnings you can see are never a run rate. They are a point on a cycle, and the arithmetic of a trough year makes a good business look like a bad one because the costs stayed while the revenue left.

Axcelis is currently sitting in that trough, and the shape of the decline says something. Revenue fell to $839.0 million in 2025 from $1,017.9 million, and systems revenue carried almost all of the damage, dropping to $571.0 million from $782.6 million. Yet the filing records that "Gross margin percent for the year was 44.9% compared to 44.7% in 2024." Holding gross margin flat while shipping a quarter fewer machines is unusual. It means the company did not buy its way through the downturn with price, which is the standard capital-equipment mistake, and it means the recovery arrives on a cost base that has not been rebuilt around discounted units.

The reason the floor exists is the installed base. About 3,400 tools sit in 27 countries, and the filing describes the attached business as "used tools, spare parts, equipment upgrades, and maintenance services". Aftermarket revenue was $268.0 million in 2025, and the labor-driven services piece within it "was $47.0 million, or 5.6% of revenue for 2025, compared with $41.0 million, or 4.0% of revenue for 2024". Read those two periods together: the services line grew in absolute dollars while total revenue fell by nearly a fifth. Fabs stop buying implanters in a downcycle. They do not stop running the ones they own.

Ion implantation is also a narrow specialty rather than a general equipment market, which changes the competitive question. The relevant rivals named in the risk factors are Advanced Ion Beam Technology, Nissin Ion Equipment and Sumitomo Heavy Industries Ion Technology, a short list of specialists rather than the diversified giants. Against the broader equipment cohort, the trailing operating margin of 11.4% sits well below Lam Research (LRCX) at 34.3% and Applied Materials (AMAT) at 28.6%, but that comparison is measuring cycle position more than business quality: ACM Research (ACMR) runs at 12.5% and Veeco (VECO) at 2.9%, and the smaller specialists move with their end markets far more violently than the leaders do.

The balance sheet lets the company wait. Borrowings are small enough that interest is covered about 17.1 times over, the filing records that "In 2025, $118.3 million of cash was provided by operating activities" even in a down year, and the share count has fallen about 2.3% a year over the four years to March 2026. A company that generates cash and retires shares through a trough is compounding the per-share claim on the recovery it is waiting for.

The bear case is that the price already assumes the recovery, and more. That is the strongest argument against owning this, and it is a valuation argument rather than a business one.

Bear Case

The balance sheet here is genuinely strong, and that is exactly the problem. Borrowings are trivial, interest is covered roughly 17.1 times over, and there is no plausible path by which this company gets into financial distress. Which means the equity has nothing structural to fall back on, because there is no restructuring, no deleveraging and no forced-seller dynamic to reverse. Book value is $33.72 a share, and everything above that line is an opinion about future orders. At today's quote, roughly three quarters of the value sits in that opinion. A cash-rich company with no debt has no floor other than what the market decides its earnings will be worth, and in capital equipment that decision changes fast.

Order flow, the thing that would justify the opinion, is moving the wrong way. The 10-K reports that "Systems backlog, including deferred systems revenue, was $457.0 million and $645.8 million as of December 31, 2025 and 2024, respectively." That is roughly a 29% decline in the visible forward book, and it happened in the year revenue already fell to $839.0 million from $1,017.9 million. Operating profit followed: "Operating profit was $119.3 million in 2025, compared to $210.8 million in 2024." Backlog is the earliest of the three to move, and it moved first and hardest.

Geography turns an industry cycle into a policy exposure. International sales were 83.7% of revenue in 2025, and ion implanter shipments to Asian customers were 76.0% of total system revenue. The filing is direct about the consequence: "Increased U.S. export controls and other political and trade tensions exacerbate the risk that Chinese customers will change suppliers to non-U.S. vendors", naming three specific Asian competitors positioned to take that business. Unlike a demand downturn, share lost to a non-U.S. vendor because of a trade rule does not come back when the cycle turns.

Now the arithmetic the price requires. At today's level the market is paying about 44 times company-wide operating income, and sustaining that requires operating profit to compound at the ceiling the business can fund from its own cash flow for roughly 20 years. Only about 14% of comparable fast growers have sustained a pace like that for even a decade. The rate itself is not the stretch, since this company has delivered rates in that range before. The duration is, and twenty years is a long time to ask of a business whose customers reset their capital budgets every eighteen months.

The methods all agree on where that leaves the price, which is unusual and not comforting. Against asset value the price sits about 3.72 times where those methods land; against earnings power about 4.1 times; against peer multiples about 1.96 times; and even against the forward growth methods about 2.3 times. No standard frame reaches today's level. That does not make the price wrong, but it does mean the entire case rests on a recovery whose leading indicator is currently declining, held for longer than most companies in this position have managed.

Valuation

At $133.91 the market is paying about 44 times company-wide operating income. Holding that requires operating profit to grow at the ceiling this business can self-fund for roughly 20 years, and only about 14% of comparable fast growers have sustained that pace over even a decade. The rate is not the demanding part. Axcelis has produced growth at that pace before. The length of time it must persist is what makes this an elevated bet rather than an ordinary one.

The margin side of the same requirement is more concrete. The price leans on an operating margin near 16.9%, against 11.4% on trailing results. So the buyer needs both: margins back toward mid-cycle and then two decades of compounding on top. Given how the trough works here, the first half of that is plausible; the filing says the industry's costs "are not easily adjusted to reflect changes in revenue", which cuts both ways and lifts margins quickly when volume returns.

What is striking is that no family of method reaches today's price. Against asset value the price sits about 3.72 times where those methods land; against earnings power about 4.1 times; against peer multiples about 1.96 times; and against the forward growth methods about 2.3 times. When every frame lands below the price, there is no lens in which the current level is the conservative read. The price is a bet beyond what the standard frames encode, and naming that plainly is more useful than choosing whichever method comes closest.

The filed inputs behind those frames are trough inputs, which is the honest caveat. Fiscal 2025 revenue was $839.0 million against $1,017.9 million in 2024, and "Operating profit was $119.3 million in 2025, compared to $210.8 million in 2024." Capitalizing that into perpetuity, which is what the earnings-power frame does, prices a cycle bottom as though it were permanent. Peer context runs the same way: ACM Research (ACMR), running a 12.5% operating margin, and Veeco (VECO) at 2.9%, show what the smaller specialists earn at this point in the cycle, while Lam Research (LRCX) at 34.3% shows what scale and leading-edge exposure earn at the same moment.

Sensitivity to rates is unusually high, and worth knowing before anything else moves. Each extra point of required return shortens the implied window by roughly 2.94 years. A move in the discount environment therefore does more to this valuation than a good quarter would.

Solvency is not the constraint and does not bound anything meaningfully here, because there is little to bound: borrowings are small, interest is covered about 17.1 times over, and share count has fallen about 2.3% a year over the four years to March 2026. The constraint is the order book, which finished 2025 carrying $457.0 million of systems backlog against $645.8 million a year earlier.

Catalysts

Second-quarter 2026 results are scheduled for August 6, 2026. The first quarter produced revenue of $199 million and earnings per share of $0.72, with roughly $5 million of a customer settlement weighing on both gross margin and the bottom line. Management guided the second quarter to about $205 million of revenue, roughly $0.90 of Q2 2026 earnings per share, and gross margin near 43%. A sequential step up of a few million dollars is not a recovery; what matters is whether gross margin holds in the low forties while the mix shifts.

The shape of the year management has described is the more informative disclosure. Full-year 2026 revenue is expected to be roughly flat against 2025, weighted toward the second half, with memory the stronger end market and gross margin in the low to mid 40% range. Flat revenue in a business whose systems backlog fell by about 29% during 2025 implies orders have to improve during the year simply to hold the line, so bookings commentary carries more information than the revenue print itself.

Memory leading the recovery would be a change in mix rather than just in volume. The company groups its end markets as memory, mature process technology, and leading-edge foundry and logic, and the mature-node business that drove the last upcycle is the one that has been correcting. A memory-led year would broaden the customer base at the same time as the aftermarket line keeps growing off an installed base of roughly 3,400 tools, which is the combination that would make the current backlog trough look like a pause rather than a trend.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• VECO (VEECO INSTRUMENTS INC.)
• FY2025 10-K: …also lead to intensified price competition resulting in lower profit margins. ​ 17 Table of Contents We operate in industries characterized by rapid technological change. ​ Each of the industries in which we operate is subject to rapid technological change. Our ability to remain competitive depends on our ability to…
• FY2025 10-K: …systems. As a result, the timing for the recognition of revenue for a single transaction could have a material effect on our sales and operating results for a particular fiscal period. As is typical in our industry, orders and shipments often occur during the last few weeks of a quarter. As a result, a delay of only…
• ACMR (ACM Research, Inc.)
• FY2025 10-K: …tools that we produce for a customer that potentially may not be accepted. Refer to "Item 1A. Risk Factors-Risks Related to Our Business and Our Industry-Difficulties in forecasting demand for our tools may lead to periodic inventory shortages or excess spending on inventory items that may not be used." Cost of…
• FY2025 10-K: …and advanced packaging (excluding ECP), services and spares. We attribute the increase to a longer-term commitment by our mainland China-based customers to increase production capacity to achieve a greater share of the global semiconductor market together with the market share changes and product cycles. The increase…
• LRCX (LAM RESEARCH CORPORATION)
• FY2025 10-K: …liability, restructuring charges, impairment of long-lived assets, and transformational charges. Segment results are derived from the Company's internal management reporting system utilizing policies that are substantially the same as those used for external reporting purposes. The CODM utilizes segment revenue…
• FY2025 10-K: …includes sales of new leading-edge equipment in deposition, etch, clean and other water fabrication markets. Customer support-related revenue includes sales of customer service, spares, upgrades, and non-leading-edge equipment from the Company's Reliant® product line. The Company operates in one reportable business…
• ASML (ASML HOLDING NV)
• FY2025 20-F: …The increase in net service and field option sales was primarily due to the growing installed base, higher levels of lithography tool use for certain customers and more NXE field upgrades. Our gross profit and gross margin increased in 2025 c ompared to 2024 , mainly driven by a favorable NXE product mix and higher…
• FY2025 20-F: …construction and demolition waste) Waste generated per €m revenue (excluding construction and demolition waste) 66% 467 kg 2024: 62% 2024: 469 kg 2025 target: 65% 2025 target: 322 kg Our sub-topics Systems Parts and tools Transport materials Non-product-related waste Real estate STRATEGIC REPORT CORPORATE GOVERNANCE…
• AMAT (APPLIED MATERIALS INC /DE)
• FY2025 10-K: …in which we operate; • the importance of increasing market positions in segments with growing demand; • manufacturers' ability to reconfigure and re-use equipment, resulting in diminished need to purchase new equipment and services from us, and challenges in providing parts for reused equipment; • the availability of…
• FY2025 10-K: …shipment schedules, this may strain our manufacturing and supply chain operations and negatively impact our working capital. If we are unable to accurately forecast demand for our products, we may purchase more or fewer parts than necessary or incur costs for canceling, postponing or expediting delivery of parts. If…
• KLAC (KLA CORPORATION)
• FY2025 10-K: …of new technologies like AI, with that region recording 27% and 18% of total revenues during fiscal years 2025 and 2024, respectively. The remaining regions accounted for less than 20% of total revenues individually in all periods. Gross margin Our gross margin fluctuates with revenue levels and product mix and is…
• FY2025 10-K: …development and manufacturing processes to enhance productivity, improve yields and reduce waste. To remain competitive, we use significant financial resources to offer a broad range of products, to maintain customer service and support centers worldwide, and to invest significantly in product R&D. In each of our…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.